Coronavirus (COVID-19), Coagulation, and Exercise: Interactions That May Influence Health Outcomes

Emma Kate Zadow, BSc (Hons.), PhD, Daniel William Taylor Wundersitz, BSc (Hons.), PhD, Diane Louise Hughes, BSc (Hons.), PhD, Murray John Adams, BSc (Hons.), PhD, Michael Ian Charles Kingsley, BPhEd, MSc, PhD, Hilary Anne Blacklock, MB ChB, Sam Shi Xuan Wu, BSc, MSc, PhD, Amanda Clare Benson, BEd (Phys. Ed), MSc, PhD, Frédéric Dutheil, MD, PhD, Brett Ashley Gordon, BAppSc, MAppSc, PhD.

1 Holsworth Research Initiative, La Trobe Rural Health School, La Trobe University, Bendigo, Victoria, Australia
2 Department of Pharmacy and Biomedical Sciences, School of Molecular Sciences, La Trobe University, Bendigo, Victoria, Australia
3 College of Science, Health, Engineering and Education, Murdoch University, Murdoch, Western Australia, Australia
4 Department of Exercise Sciences, University of Auckland, Auckland, New Zealand
5 Department of Haematology, Middlemore Hospital, Auckland, New Zealand
6 Department of Health and Medical Sciences, Swinburne University of Technology, Hawthorn, Victoria, Australia
7 Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, Clermont-Ferrand, France

Address for correspondence Emma Kate Zadow, BSc (Hons), PhD, Holsworth Research Initiative, La Trobe Rural Health School, La Trobe University, Edwards Road, Flora Hill, Bendigo, Victoria 3550, Australia (e-mail: e.zadow@latrobe.edu.au).

Abstract

The proinflammatory cytokine storm associated with coronavirus disease 2019 (COVID-19) negatively affects the hematological system, leading to coagulation activation and endothelial dysfunction and thereby increasing the risk of venous and arterial thrombosis. Coagulopathy has been reported as associated with mortality in people with COVID-19 and is partially reflected by enhanced D-dimer levels. Poor vascular health, which is associated with the cardiometabolic health conditions frequently reported in people with severer forms of COVID-19, might exacerbate the risk of coagulopathy and mortality. Sedentary lifestyles might also contribute to the development of coagulopathy, and physical activity participation has been inherently lowered due to at-home regulations established to slow the spread of this highly infectious disease. It is possible that COVID-19, coagulation, and reduced physical activity may contribute to generate a “perfect storm,” where each fuels the other and potentially increases mortality risk. Several pharmaceutical agents are being explored to treat COVID-19, but potential negative consequences are associated with their use. Exercise is known to mitigate many of the identified side effects from the pharmaceutical agents being trialled but has not yet been considered as part of management for COVID-19. From the limited available evidence in people with cardiometabolic health conditions.

Keywords
► coronavirus
► pharmaceutical medications
► coagulation
► fibrinolysis
► physical activity

Semin Thromb Hemost 2020;46:807–814.

published online September 3, 2020
Issue Theme Maintaining Hemostasis and Preventing Thrombosis in COVID-19
Part I: Guest Editors: Emmanuel J. Favaloro, PhD, FFSc (RCPA), and Giuseppe Lippi, MD.
COVID-19 and Coagulopathy

It has been reported that up to 68% of people diagnosed with COVID-19 and needing intensive care have preexisting comorbidities known to affect the vascular system, including hypertension, cardiovascular disease, hypercholesterolemia, and diabetes. These conditions typically stem from, or contribute to, the metabolic syndrome, which is associated with increased amounts of visceral adipose tissue. This tissue is known to secrete several cytokines that are implicated in the inflammatory cascade, leading to a state of low-grade inflammation. Reports on clinical characteristics of COVID-19 intensive care patients include elevated cytokine levels such as interleukin (IL)-2, IL-7, IL-10, granulocyte colony-stimulating factor, interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP1), macrophage inflammatory protein-1 α (MIP1A), and tumor necrosis factor-α (TNFα). Activation of these cytokines can result in an inflammatory cascade, leading to coagulation activation and endothelial dysfunction.

Elevated levels of proinflammatory cytokines might partially explain the large number of COVID-19 infected individuals presenting with coagulopathy, particularly evident in older people and those with cardiometabolic comorbidities. Elevated D-dimer concentrations >1,000 ng/mL were associated with an eightfold increased odds of fatal outcome, suggesting coagulopathy to be a predictor of mortality risk in individuals with COVID-19.

D-dimer is a widely used clinical biomarker of endogenous fibrin clot formation and a well-recognized laboratory marker of hypercoagulability (coagulation activation). Elevated D-dimer levels in people with COVID-19 are associated with a higher risk of intensive care unit admission or death. The mortality risk associated with higher levels of D-dimer is particularly evident in older people and those with cardiometabolic comorbidities. In addition to elevated D-dimer levels, Tang et al reported significantly higher levels of FDPs and prolonged immobility. The resulting coagulation abnormalities are recognized as "COVID-19-associated coagulopathy."
prolonged prothrombin time (PT) in COVID-19 nonsurvivors compared with those who survived. Therefore, it can be suggested that these conventional parameters of coagulation are significantly associated with overall prognosis.

**Physical Activity and Risk for Coagulopathy**

A common behavioral feature, and risk factor, for the comorbidities associated with COVID-19 is insufficient physical activity. A diagnosis of COVID-19, whether mild or severe symptoms occur, is likely to reduce physical activity even further in those required to isolate in the home environment or be bedbound in a hospital setting. While under instructions to self-isolate indoors to slow the outbreak of COVID-19, data obtained by smartwatches have demonstrated that weekly physical activity has decreased by 9% to 48%. This reduction in physical activity is frequently associated with venous thromboembolism, which typically consists of pulmonary embolism or deep vein thrombosis. These major clinical problems negatively alter blood coagulability and have potential life-threatening consequences, such as acute cardiac injury and/or sudden death. Therefore, it may be that COVID-19, coagulopathy, and reduced physical activity contribute to generate a "perfect storm," where each fuels the other and potentially increases mortality risk. Physical activity can induce many health benefits and can positively modify coagulation markers in healthy populations. High cardiorespiratory fitness has been suggested to offer some protection against the deleterious effects of COVID-19 and consequently it is important to safely participate in physical activity during this pandemic. Therefore, early intervention through physical activity or exercise might mitigate negative health consequences and reduce mortality risk in people with mild or moderate COVID-19. However, at this point, it is not clear if, or how, physical activity or exercise can be used as part of the overall treatment process for coagulopathy associated with COVID-19.

**Exercise and Hemostasis**

Exercise (planned physical activity completed specifically for the purpose of improving health and fitness) has been demonstrated to have considerable effects on hemostasis by positively modifying markers of coagulation and fibrinolytic response in apparently healthy populations. Low- to moderate-intensity exercise is likely to reduce the risk of coagulopathy; however, acute bouts of high-intensity exercise may act as a potential trigger for increased thrombotic risk due to an increase in venous blood flow, blood viscosity, and laminar shear stress, activating the coagulation system. Nonetheless, the influence of acute bouts of exercise on coagulation and fibrinolysis have often produced conflicting data due to various factors including varying study protocols and exercise modes. It is evident that exercise intensity plays an influential role in shifting the equilibrium between coagulation and fibrinolysis, with strenuous (high-intensity) exercise consistently demonstrated to increase hemostatic activation as opposed to low- to moderate-intensity exercise. For apparently healthy individuals, exercise completed at a higher intensity appears to increase clot degradation, probably in response to coagulation activity. This is evidenced by an increase in overall fibrinolytic activity when cycling at 70% VO2 max compared with 40% VO2 max but also an approximately 50% increase in t-PA activity when cycling at 80% VO2 max compared with 50% VO2 max. Furthermore, Menzel and Hilberg observed increased thrombin–antithrombin complexes when cycling at 100% but not at 80% individual anaerobic threshold. These findings indicate that exercise intensity is an important contributor to thrombin generation through activation of both the coagulation and fibrinolytic systems, albeit in a healthy population, and it is clear that to minimize the risk of coagulopathy, moderate- to high-intensity exercise should be avoided by untrained, inappropriately trained, or sedentary individuals. Despite this, there remains an opportunity to explore the use of exercise as an adjuvant therapeutic tool in the management and prevention of COVID-19-associated coagulopathy.

Separate to acute responses to exercise, individuals who are regularly physically active possess a "thromboprotective element," whereas individuals who are not regularly active or those with a preexisting medical condition have attenuated fibrinolytic responses in combination with exaggerated changes in procoagulant and platelet variables. When investigating coagulation and fibrinolytic responses in relation to exercise in physically inactive individuals and those with varying medical conditions (i.e., peripheral arterial disease, metabolic syndrome, hemiparetic strokes, and hypertension), exercise intensity varied between 50% and 70% VO2 max. Exercise performed at 50% VO2 max increased fibrinolytic activity in both active and inactive apparently healthy males, but larger increases in t-PA were observed only in physically inactive males. In sedentary males with metabolic syndrome, exercise at 70% VO2 max reduced fibrinolytic activity and these individuals remained hypofibrinolytic compared with non-obese sedentary males. In middle-aged females with previous myocardial infarction, Eriksson-Berg et al demonstrated increased fibrinolytic activity following exercise at 50% maximal work capacity, whereas markers of coagulation activation remained undisrupted. Low- to moderate-intensity exercise in people with varying medical conditions increases fibrinolytic activity, as evidenced by elevated t-PA concentrations, which may persist up to 1 hour postexercise. Therefore, even for individuals with existing cardiometabolic health conditions associated with worse COVID-19 outcomes, lower intensity exercise may have thromboprotective effects. It is then possible that low- to moderate-intensity exercise may increase acute fibrinolytic activity and reduce COVID-19-associated blood clot formation. However, to date, no studies have investigated how exercise might impact the hemostatic profile within this population.

**COVID-19, Pharmaceutical Agents, and Exercise**

No universal pharmaceutical treatment for COVID-19 is as yet available, although multiple therapeutic strategies are
being attempted and trialled. These relate to pharmacological agents that (1) block viral entry to host cells through the prevention of attachment or fusion, or removal of virus by immune cells, or the use of hyperimmune plasma, (2) block viral replication and survival in host cells through viral protease inhibition or viral nucleic acid and protein synthesis inhibition, (3) dampen the exaggerated immune response through corticosteroids, cytokine blockade, or intravenous immunoglobulin, and/or (4) inhibit the abnormal prothrombotic response by anticoagulants.

Due to the broad range of pharmaceutical agents being trialled for COVID-19, and the apparent impact of the virus on hematological parameters that are associated with poor prognosis and mortality, it is critical to examine the possible pharmaceutical agent interactions with exercise. Table 1 indicates the broad class of pharmaceutical agents being trialled for COVID-19, potential consequences associated with their use, and implications for exercise.

### Table 1 Classes of pharmaceutical agents being trialled for COVID-19, intended action, potential side effects associated with their use, and considerations for exercise

| Pharmaceutical class | Intended action | Potential side effects/interactions | Consideration for exercise |
|----------------------|----------------|------------------------------------|---------------------------|
| **Anticoagulants**   | Suppression of synthesis/function of various clotting factors to prevent the formation of blood clots | Hemorrhage, Thrombocytopenia, Hypersensitivity reactions, Adverse interactions with other drugs that bind to plasma proteins or are metabolized by the liver | ↑ Blood fluidity & blood flow, ↓ oxygen delivery. Exercise induced hypotension |
| **Antiviral agents** | Blocks viral entry to host cells • Serine protease inhibitors Blocks viral replication in host cells Inhibits angiotensin-converting enzyme (2) | Joint and/or muscle pain, Headaches, dizziness, nausea, Cough, nasal congestion, fever, body aches, malaise, and, in severe cases, death | J-shaped hypothesis for exercise dose and infection risk. ↓ muscle control due to neuropathy & muscle weakness |
| **Corticosteroids**  | Regulates gene expression to suppress inflammation and immune responses | Can ↑ risk and severity of infections, as well as masking infections. May cause elevated blood glucose levels, fluid retention, or elevated blood pressure. Long-term use may suppress the immune system. May ↑ gastrointestinal symptoms. Can ↓ bone density, cause osteoporosis, and ↑ risk of fractures. Affects metabolism fat deposition. Impaired ability to sleep. Mood changes (>30 mg/day). Eye problems. Atherosclerosis and aseptic necrosis (long-term use and high doses). Withdrawal can cause fatigue, joint pain, muscle stiffness and tenderness, or fever | > 2 wk use ↓ ability of the body to respond to physical stress. Muscle weakness in people who may already be strength compromised. Potential for impaired physiological response to exercise due to adrenal gland dysfunction. Potential for impaired neural signaling, muscle damage, and muscle weakness. |
| **Nonsteroidal anti-inflammatory drugs** | Inhibits COX-1 or COX-2 enzymes, thus stopping prostaglandin production Blocks toll-like receptors involved in cytokine production | Gastrointestinal irritation, fluid retention, and elevated blood pressure. ↑ Risk heart attack and stroke, dizziness, light-headedness, tiredness, headache, ringing in the ears | During prolonged exercise, they may strain the kidneys and ↓ the ability of the muscle to recover. ↑ Exacerbate risk of injury as it masks musculoskeletal pain. ↑ Blood pressure response with exercise, particularly with higher intensities. ↓ Capacity for skeletal muscle oxygen transfer ↓ energy availability. |
| **Disease-modifying antirheumatoid drugs** | Antimalarial • Destruction of parasite | May be immunosuppressive, myelosuppressive, cause cardiac toxicity, or severe low blood glucose levels | Myelosuppressive side effects could impair exercise capacity. Reliance on aerobic energy metabolism. Additional thermoregulation required. |

Notes: ↑ increased; ↓ reduced/decreased. Intended action and potential side effects information obtained from the Australian Medicines Handbook (https://amhonline.amh.net.au/auth). This table is a general review only and is not specific to individual drugs. For a more empiric or investigational use of individualized agents with antithrombotic properties in COVID-19, please see the review by Bikdeli et al.15
Antiviral agents previously used to treat influenza have been reported to be effective for treating COVID-19. When these have been used in combination with immune system pharmaceuticals (i.e., antimalarial and protease inhibitors), symptoms have been alleviated, along with reduced viral shedding and hospital stay. Recognized side effects of antiviral agents include fatigue, dizziness, and poor mental health. Antimalarial agents have some common side effects with antiviral drugs, including dizziness and mental health issues along with other exercise prescription considerations such as muscle weakness, cardiac arrhythmia, and heart failure. Protease inhibitors also have the potential to induce cardiac arrhythmia and reduce metabolic control. Therefore, the use of exercise as an adjuvant therapy might be appropriate given the positive effects of exercise on all of the potential adverse reactions to the pharmaceutical agents (i.e., enhanced mood/mental health, cardiovascular and metabolic health, along with the strong potential of low-to-moderate-intensity exercise to directly affect the coagulation process. However, the setting and mode for exercise delivery needs to be carefully selected, thus avoiding the potential consequences of exacerbating symptoms of dizziness and the potential for falling and further injury.

Conclusion

The association of abnormal coagulation with severe pneumonia and death in people with COVID-19 has led to reports on thromboembolic complications. This seems to be more apparent in people who also have cardiometabolic health conditions. Particularly in people who have mild or moderate symptoms of COVID-19, and perhaps those with more severe COVID-19, low- to moderate-intensity exercise could be regarded as adjuvant therapy to assist with minimizing the potential adverse reactions of the infection and any treatment-related issues. Furthermore, low- to moderate-intensity exercise might be important to contribute to reducing the risk of developing more severe forms of COVID-19 and further reducing the risk of coagulopathy that seems to be associated with mortality. Yet, enhanced social distancing (i.e., at least 2 m) while practicing outdoor sport and exercise would be mandatory since airborne virus propagation is considerably higher during physical exercise.

Conflict of Interest

None.

References

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395 (10223):497–506
2. Wen J, Aston J, Liu X, Ying T. Effects of misleading media coverage on public health crisis: a case of the 2019 novel coronavirus outbreak in China. Anatolia 2020;31:331–336
3. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/. Accessed 22 May, 2020
4. UNCTAD. Coronavirus: can policymakers aver a trillion-dollar crisis? Available at: https://unctad.org/en/pages/newsdetails.aspx?OriginalVersionID=2300. Accessed April 30, 2020
5. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020;506:145–148
6. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63(01):364–374
7. Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV [in Chinese]. Zhonghua Xue Guan Bing Za Zhi 2020;48(00):E004
8. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020;95 (07):834–847
9. Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020;92(07):791–796
10. Cannegieter SC, Klok FA. COVID-19 associated coagulopathy and thromboembolic disease: commentary on an interim expert guidance. Res Pract Thromb Haemost 2020;4(04):439–445
11. Pallister CJ, Watson MS. Haematology. 2nd ed. Banbury, UK: Scion Publishing; 2010
12. Lowe GD. Virchow’s triad revisited: abnormal flow. Pathophysiol Haemost Thromb 2003;33(5-6):455–457
13. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58(07):1021–1028
14. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020;7 (06):e438–e440
15. Bikdeli B, Madhavan MV, Gupta A, et al; Global COVID-19 Thrombosis Collaborative Group. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020 (e-pub ahead of print). Doi: 10.1055/s-0040-1713152
16. Hashemi A, Madhavan MV, Bikdeli B. Pharmacotherapy for prevention and management of thrombosis in COVID-19. Semin Thromb Hemost 2020 (e-pub ahead of print). Doi: 10.1055/s-0040-1714273
17. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006;26(01):41–48
18. Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013;93(01):327–358
19. Verhamme P, Hoylaerts MF. The pivotal role of the endothelium in haemostasis and thrombosis. Acta Clin Belg 2006;61(05):213–219
20. Kleinegris MC, Ten Cate-Hoek AJ, Ten Cate H. Coagulation and the vessel wall in thrombosis and atherosclerosis. Pol Arch Med Wewn 2012;122(11):557–566
21. Siahkouhian M, Khodadadi D, Bolboli L. Diurnal variation of the haemostatic response to exercise in young sedentary males. Biol Sport 2013;30(02):125–130
22. Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Semin Thromb Hemost 2020;46(03):302–319
23. Larsen JB, Pasalic L, Hvas AM. Platelets in coronavirus disease 2019. Semin Thromb Hemost 2020 (e-pub ahead of print). Doi: 10.1055/s-0040-1710006
24. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 (e-pub ahead of print). Doi: 10.1001/jama.2020.1585
25. Prchal JT. Hypoxia and thrombosis. Blood 2018;132(04):348–349
26. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res 2019;181:77–83
27. Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis
or pulmonary embolism? Semin Thromb Hemost 2020 (e-pub ahead of print). Doi: 10.1055/s-0040-1712155
28 Kwaan HC. Coronavirus disease 2019: the role of the fibrinolytic system from transmission to organ injury and sequelae. Semin Thromb Hemost 2020 (e-pub ahead of print). Doi: 10.1055/s-0040-1709996
29 Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091
30 Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–1720
31 Grasselli G, Zangrillo A, Zanella A, et al; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323(16):1574–1581
32 Dutheil F, Gordon BA, Naughton G, et al. Cardiovascular risk of adipokines: a review. J Int Med Res 2018;46(06):2082–2095
33 Koehler KS, Bottoni T. The effect of exercise on D-dimer levels. Thromb Res 2019;180:37–41
34 Henke PK, Pannucci CJ. Venous thromboembolism risk factor assessment and prophylaxis. Phlebology 2010;25(05):219–223
35 Kelly J, Rudd A, Lewis RR, Hunt BJ. Plasma D-dimers in the diagnosis of venous thromboembolism. Arch Intern Med 2002;162(07):747–756
36 Prisco D, Paniccia R, Bandinelli B, et al. Evaluation of clotting and fibrinolytic activation after protracted physical exercise. Thromb Res 1998;89(02):73–78
37 Schobersberger W, Wirleitner B, Puschendorf B, et al. Inflammatory and coagulation markers in the blood of an ultramarathon race at moderate altitude on coagulation and fibrinolysis. Fibrinolysis 1995;10(01):37–42
38 Schoersberger W, Wirlleiter B, Buschendorf B, et al. Influence of an ultramarathon race at moderate altitude on coagulation and fibrinolysis. Fibrinolysis 1995;10(01):37–42
39 Nguyen NT, Owings JT, Gosselin R, et al. Systemic coagulation and fibrinolysis after laparoscopic and open gastric bypass. Arch Surg 2001;136(08):909–916
40 Parker BA, Augeri AL, Capizzi JA, et al. Effect of marathon run and air travel on pre- and post-run soluble d-dimer, microparticle procoagulant activity, and p-selectin levels. Am J Cardiol 2012;109(10):1521–1525
41 Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349(13):1227–1235
42 Koehler KS, Bottini T. The effect of exercise on D-dimer levels. Mil Med 2014;179(02):225–230
43 Schweler S, Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost 2020 (e-pub ahead of print). Doi: 10.1055/s-0040-1710337
44 Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Hemost 2020;120(05):876–878
45 Haskell WL, Lee IM, Pate RR, et al; American College of Sports Medicine; American Heart Association. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007;116(09):1081–1093
46 Lippi G, Henry BM, Sanchis-Gomar F. Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019 (COVID-19). Eur J Prev Cardiol 2020;27(09):906–908
47 Lippi G, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018;44(08):780–786
48 Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med 2020;8(07):497
49 FithiStaffThe impact of coronavirus on global activity. Available at: https://blog.fitbit.com/covid-19-global-activity/. Accessed May 29, 2020
50 Evidation Health. COVID-19 Pulse Study. Available at: https://evidation.com/news/covid-19-pulse-first-data-evidation/. Accessed May 28, 2020
51 Goldhaber SZ, Bournaneaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379(9828):1835–1846
52 Hull CM, Harris JA. Cardiology Patient Page. Venous thromboembolism and marathon athletes. Circulation 2013;128(25):e469–e471
53 Gregson J, Kaptoge S, Bolton T, et al; Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 2019;4(02):163–173
54 Lippe G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018;44(08):780–786
55 Lippe G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med 2020;8(07):497
56 Garber CE, Blissem B, Deschenses MR, et al; American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011;43(07):1334–1359
57 Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, et al; American College of Sports Medicine. American College of Sports Medicine position stand. Exercise and physical activity for older adults. Med Sci Sports Exerc 2009;41(07):1510–1530
58 Panagiotakos DB, Pitsavos C, Chrysohoou C, Kavousas S, Stefanadis C; ATTICA Study. The associations between leisure-time physical activity and inflammatory and coagulation markers related to cardiovascular disease: the ATTICA Study. Prev Med 2005;40(04):432–437
59 Pitsavos C, Panagiotakos DB, Chrysohoou C, Kavousas S, Stefanadis C. The associations between physical activity, inflammation, and coagulation markers, in people with metabolic syndrome: the ATTICA study. Eur J Cardiovasc Prev Rehabil 2005;12(02):151–158
60 Zbinden-Foncea H, Francaux M, Delclique L, Hawley JA. Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2? Obesity (Silver Spring) 2020(Apr):23
61 Chen P, Mao L, Nassis GP, Hamer P, Ainsworth BE, Li F. Coronavirus disease (COVID-19): the need to maintain regular physical activity while taking precautions. J Sport Health Sci 2020;9(02):103–104
62 Szynanski LM, Pate RR. Fibrinolytic responses to moderate intensity exercise. Comparison of physically active and inactive men. Arterioscler Thromb 1994;14(11):1746–1750
63 Thrall G, Lane D, Carroll D, Lip GYH. A systematic review of the effects of acute psychological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: implications for the pathogenesis of acute coronary syndromes. Thromb Res 2007;120(06):819–847
64 el-Sayed MS. Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. Sports Med 1996;22(05):282–298
65 Ferguson EW, Bernier LL, Banta CR, Yu-Yahiro J, Schoemaker EB. Effects of exercise and conditioning on clotting and fibrinolytic activity in men. J Appl Physiol (1985) 1987;62(04):1416–1421
66 Karampour S, Gaeni AA. Response of coagulation and anti-coagulant factors of elite athletes following acute resistance and high-intensity interval training. J Sports Med Phys Fitness 2018;58(1-2):120–126
67 Kupchak BR, Creighton BC, Aritizababal JC, et al. Beneficial effects of habitual resistance exercise training on coagulation and fibrinolytic responses. Thromb Res 2013;111(06):e227–e234
68 Eriksson-Berg M, Egberg N, Eksborg S, Schenck-Gustafsson K. Retained fibrinolytic response and no coagulation activation
109 Polman R, Kaiseler M, Borkoles E. Effect of a single bout of exercise on the mood of pregnant women. J Sports Med Phys Fitness 2007;47(01):103–111

110 Yeung RR. The acute effects of exercise on mood state. J Psychosom Res 1996;40(02):123–141

111 Pollock MLGG, Butcher JD, et al. American College of Sports Medicine position stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc 1998;30(06):975–991

112 Lippi G, Henry BM, Bovo C, Sanchis-Gomar F. Health risks and potential remedies during prolonged lockdowns for coronavirus disease 2019 (COVID-19). Diagnosis (Berl) 2020;7(02):85–90

113 Halabchi F, Ahmadinejad Z, Selk-Ghaffari M. COVID-19 epidemic: exercise or not to exercise; that is the question!. Asian J Sports Med 2020 (e-pub ahead of print). Doi: 10.5812/asjsm.102630